



Background information

Facts & Figures

The Division Animal Health

As of June 2007

Net sales 2006:	905 EURm
Employees:	2,800
Global ranking:	4
Headquarters:	Monheim, Germany

Particularly, infectious diseases and parasites are a threat to animal health. In addition, food safety is at stake for productive livestock. Furthermore, for farmers, animal health is a significant economic factor. With pets – such as dogs and cats – emotional factors are of greater importance. However, diseased pets can also impair human health, for example, by transmitting germs. In these areas, the Animal Health division of Bayer HealthCare takes the responsibility by offering medications against germs in animals.

The division produces and markets around 100 animal medicines and care products for productive livestock and pets. It is one of the most successful providers in the field of veterinary medicine, ranking in fourth place internationally. Especially in the continuously growing market for pets, the Animal Health division is well-positioned with its products against parasite diseases. Hence, the Advantage product family that consists of ectoparasiticides for dogs and cats ranks in third place within the top-selling Consumer Health products of Bayer HealthCare with annual net sales amounting to 275 EURm. The Drontal product line against tapeworms in dogs and cats is also well accepted among pet owners. For many years, the antibiotic, Baytril, has set the standards in the treatment of severe infectious diseases in productive livestock and pets among veterinarians. Another important Animal Health product is Baycox, which is

used for the treatment of coccidiosis – a dangerous intestinal disease in poultry and pigs. In addition to offering products against infectious diseases and parasites, Animal Health markets vaccines for productive livestock, as well as dietary supplements and care products for pets in various countries around the globe.

Furthermore, innovations steadily expand the product range. Two of the most recent products for pets are Advocate and Profender – further proof of the pioneer work of Bayer HealthCare in the field of parasite treatments. The easily applicable Advocate reliably protects dogs and cats against internal and external parasites. Profender has been marketed in Europe since 2005 and is known to be the first spot-on broad spectrum endoparasiticide for cats worldwide. In 2006, Profender was awarded as the best medication for small animals by an internationally renowned jury.

Both Advocate and Profender are novel formulations for external application, which relieves animals – especially cats – from the burden of having to swallow the medication.

With sales in 2006 amounting to 905 EURm, Animal Health generated 7.7 percent of total Bayer HealthCare sales. The largest proportion of sales, amounting to 38 percent, were generated in the region Europe/Japan/MERA, followed by North America (37 percent), Latin America (12 percent) and Asia (12 percent). The division is represented in more than 120 countries worldwide.

Animal Health engages 2,800 employees around the globe. The headquarters of the division are Monheim, Germany. The research and development functions are also concentrated there. The animal medications and care products are mainly produced in Germany and the U.S. In addition, there are regional production sites.

Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma and as Bayer HealthCare Pharmaceuticals in the US and Canada. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide.

Contact:

Dr. Hermann-Josef Baaken, Tel.: +49 214 30 53366

E-mail: hermann-josef.baaken@bayerhealthcare.com

Forward-looking statements

This information contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.